Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TYRA

Tyra Biosciences Inc

Dec 12 • 04:00PM ET

15.17

Dollar change -0.46
Percentage change -2.94	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE TGTX SRRK MREO TIL MCRB ADAP HOOK XFOR PSTX

| Held by: VTI IWM VXF IWO SCHA VTWO IWC ITOT ONEQ VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.61	Insider Own	41.91%	Shs Outstand	52.87M	Perf Week	0.00%
Market Cap	767.64M	Forward P/E	-	EPS next Y	-2.04	Insider Trans	4.18%	Shs Float	30.71M	Perf Month	-4.83%
Income	-83.74M	PEG	-	EPS next Q	-0.49	Inst Own	52.46%	Short Float	6.54%	Perf Quarter	-28.58%
Sales	0.00M	P/S	-	EPS this Y	3.00%	Inst Trans	-18.52%	Short Ratio	5.98	Perf Half Y	-23.58%
Book/sh	6.85	P/B	2.21	EPS next Y	-29.64%	ROA	-27.06%	Short Interest	2.01M	Perf Year	16.25%
Cash/sh	7.12	P/C	2.13	EPS next 5Y	-	ROE	-28.66%	52W Range	11.24 - 29.60	Perf YTD	9.53%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-102.86%	ROI	-22.74%	52W High	-48.75%	Beta	1.01
Dividend TTM	-	Quick Ratio	29.55	Sales past 5Y	0.00%	Gross Margin	-	52W Low	34.96%	ATR (14)	0.97
Dividend Ex-Date	-	Current Ratio	29.55	EPS Y/Y TTM	-15.50%	Oper. Margin	-	RSI (14)	38.98	Volatility	4.70% 5.13%
Employees	49	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	31.00
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	17.33%	Payout	-	Rel Volume	0.42	Prev Close	15.63
Sales Surprise	-	EPS Surprise	-2.81%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	336.28K	Price	15.17
SMA20	-3.52%	SMA50	-19.57%	SMA200	-20.06%	Trades		Volume	139,622	Change	-2.94%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-18-24	Upgrade	BofA Securities	Neutral → Buy	$22 → $31
Aug-15-24	Initiated	Piper Sandler	Overweight	$33
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$25 → $15
Jun-30-23	Initiated	Wedbush	Outperform	$27
Feb-03-23	Initiated	Oppenheimer	Outperform	$17
Jun-23-22	Initiated	H.C. Wainwright	Buy	$12
Mar-08-22	Upgrade	Jefferies	Hold → Buy	$31 → $27
Nov-08-21	Downgrade	Jefferies	Buy → Hold
Oct-11-21	Initiated	Jefferies	Buy	$19
Oct-11-21	Initiated	Cowen	Outperform
Oct-11-21	Initiated	BofA Securities	Buy	$22

Show Previous Ratings

Nov-13-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Nov-07-24 04:05PM	Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights (PR Newswire) -6.06%
Oct-28-24 07:00AM	Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) (PR Newswire) -9.30%
Oct-24-24 06:05PM	Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) (PR Newswire) -23.35%
Oct-23-24 04:05PM	Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET (PR Newswire)
09:07PM	Loading…
Oct-22-24 09:07PM	RA Capital Management, L.P. Reduces Stake in Tyra Biosciences Inc (GuruFocus.com)
Oct-18-24 02:34PM	BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug (Benzinga) +5.20%
Oct-16-24 01:01AM	Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc (GuruFocus.com) +5.89%
Oct-11-24 08:00AM	Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) (PR Newswire)
Sep-11-24 04:05PM	Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference (PR Newswire) -5.22%
Sep-10-24 04:05PM	Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer (PR Newswire)
Sep-09-24 09:55AM	Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet (Zacks)
Aug-27-24 07:50PM	Tyra Biosciences, Inc. (TYRA): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-07-24 11:54PM	TYRA Stock Earnings: Tyra Biosciences Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights (PR Newswire)
04:05PM	Loading…
Jul-02-24 04:05PM	Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH) (PR Newswire)
Jun-07-24 12:00PM	Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High? (Zacks)
May-23-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
May-09-24 10:54PM	TYRA Stock Earnings: Tyra Biosciences Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights (PR Newswire)
May-07-24 04:05PM	Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors (PR Newswire)
Mar-19-24 09:53PM	TYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023 (InvestorPlace) +7.89%
09:01PM	Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline Progress (GuruFocus.com)
04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights (PR Newswire)
Mar-05-24 11:27PM	Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 Shares (GuruFocus.com)
Mar-01-24 12:40AM	Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 8,644 Shares (GuruFocus.com)
Feb-27-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Feb-07-24 04:05PM	Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference (PR Newswire)
03:12AM	President and CEO Todd Harris Sells 100,000 Shares of Tyra Biosciences Inc (TYRA) (GuruFocus.com)
08:00AM	Loading…
Feb-02-24 08:00AM	Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing (PR Newswire) +29.29%
Feb-01-24 05:30PM	Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia (PR Newswire)
Dec-29-23 06:45AM	16 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-22-23 09:00AM	Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300 (PR Newswire)
Nov-08-23 04:05PM	Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference (PR Newswire)
Nov-07-23 04:05PM	Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights (PR Newswire) -5.00%
Sep-21-23 08:00AM	Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings (PR Newswire)
Sep-12-23 04:05PM	Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference (PR Newswire)
Aug-10-23 04:05PM	Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights (PR Newswire)
Aug-01-23 08:00AM	Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia (PR Newswire)
Jun-16-23 08:50AM	Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price Strength (Zacks) +6.25%
Jun-07-23 09:55AM	Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet (Zacks) -5.63%
May-25-23 08:00AM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
May-23-23 08:50AM	What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing' (Zacks)
May-22-23 09:55AM	Wall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to Trade (Zacks)
Apr-09-23 09:30AM	Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation (Simply Wall St.)
Mar-29-23 04:05PM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Mar-27-23 08:50AM	Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA) (Zacks)
Mar-22-23 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights (PR Newswire) -5.01%
Mar-01-23 08:40AM	Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings? (Zacks)
07:00AM	Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia (PR Newswire)
Feb-22-23 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire) -7.99% -9.04%
Nov-29-22 07:00AM	Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300 (PR Newswire)
Nov-24-22 09:55AM	How Much Upside is Left in Tyra Biosciences, Inc. (TYRA)? Wall Street Analysts Think 184% (Zacks)
Nov-10-22 04:20PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Nov-08-22 09:55AM	Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 179%: Read This Before Placing a Bet (Zacks)
Nov-03-22 04:05PM	Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights (PR Newswire) -7.00%
Nov-02-22 04:05PM	Tyra Biosciences Announces Planned Chief Financial Officer Transition (PR Newswire)
Oct-31-22 09:22AM	We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth (Simply Wall St.)
Oct-13-22 08:00AM	Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (PR Newswire) +5.46%
Sep-08-22 04:05PM	Tyra Biosciences to Participate at September 2022 Investor Conferences (PR Newswire) +8.24%
Sep-05-22 08:15AM	Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress (PR Newswire)
Aug-04-22 04:05PM	Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights (PR Newswire) +14.97%
May-24-22 08:55AM	Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation (Simply Wall St.) -5.68%
May-05-22 04:05PM	Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights (PR Newswire)
Mar-03-22 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights (PR Newswire) -10.21%
Feb-22-22 04:05PM	Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference (PR Newswire)
Dec-21-21 06:38PM	Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ... (GuruFocus.com) +14.48%
Dec-15-21 09:29AM	Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-10-21 04:05PM	Tyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference (PR Newswire)
Nov-03-21 04:05PM	Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights (PR Newswire) +19.92% +8.25%
Sep-22-21 08:22AM	3 Stocks Insiders Are Buying (Benzinga) -7.11%
Sep-20-21 07:52AM	3 Stocks Insiders Are Buying (Benzinga) -6.83%
Sep-17-21 05:28AM	56 Biggest Movers From Yesterday (Benzinga)
Sep-15-21 10:41AM	Tyra Biosciences stock soars more than 60% on public debut (MarketWatch)
Sep-14-21 09:00PM	Tyra Announces Pricing of Upsized Initial Public Offering (PR Newswire)
06:51AM	Tyra Biosciences upsizes IPO to 9 million shares vs. prior 6.7 million for valuation of up to $626 million (MarketWatch)

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNAP, enables the rapid and precise refinement of structural design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tada Hiroomi	Officer	Dec 09 '24	Proposed Sale	15.90	10,000	159,000		Dec 09 05:42 PM
Tada Hiroomi	Officer	Dec 05 '24	Proposed Sale	15.00	5,000	75,000		Dec 05 04:21 PM
Tada Hiroomi	Officer	Dec 02 '24	Proposed Sale	16.00	5,000	80,000		Dec 02 07:06 PM
Kjellson Nina S	Director	Nov 25 '24	Sale	16.84	5,272	88,773	448,692	Nov 26 04:47 PM
Tada Hiroomi	Officer	Nov 20 '24	Proposed Sale	15.47	10,000	154,700		Nov 20 04:29 PM
Tada Hiroomi	Officer	Nov 14 '24	Proposed Sale	15.94	10,107	161,106		Nov 14 05:52 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 08 '24	Buy	16.25	1,220,681	19,836,066	8,697,956	Nov 13 05:00 PM
Kjellson Nina S	Director	Nov 06 '24	Sale	17.18	52,491	901,559	451,629	Nov 08 04:43 PM
Kjellson Nina S	Director	Nov 07 '24	Sale	17.32	22,091	382,574	449,258	Nov 08 04:43 PM
Kjellson Nina S	Director	Nov 05 '24	Sale	16.77	10,493	175,950	457,264	Nov 06 07:24 PM
Kjellson Nina S	Director	Nov 04 '24	Sale	17.01	1,076	18,298	458,390	Nov 06 07:24 PM
Kjellson Nina S	Director	Oct 31 '24	Sale	16.46	100,140	1,648,264	461,457	Nov 01 06:18 PM
Kjellson Nina S	Director	Nov 01 '24	Sale	16.56	27,493	455,272	458,506	Nov 01 06:18 PM
Kjellson Nina S	Director	Oct 30 '24	Sale	16.17	11,078	179,120	472,207	Nov 01 06:18 PM
Fuhrman Alan	Chief Financial Officer	Oct 30 '24	Buy	16.00	9,500	151,954	12,849	Nov 01 04:22 PM
Canaan XI, LP	Director	Oct 30 '24	Proposed Sale	16.00	234,000	3,744,000		Oct 30 04:01 PM
Canaan 2020 + Co-Investment, L	Director	Oct 30 '24	Proposed Sale	16.00	26,000	416,000		Oct 30 04:01 PM
Tada Hiroomi	Officer	Oct 28 '24	Proposed Sale	21.93	38,000	833,340		Oct 28 05:15 PM
Harris Todd	President and CEO	Oct 18 '24	Sale	27.01	43,636	1,178,796	1,375,011	Oct 22 05:13 PM
Harris Todd	President and CEO	Oct 21 '24	Sale	27.90	19,084	532,451	1,355,927	Oct 22 05:13 PM
Harris Todd	President and CEO	Oct 16 '24	Sale	26.17	33,297	871,430	1,434,041	Oct 17 08:12 PM
Harris Todd	President and CEO	Oct 17 '24	Sale	25.85	15,394	397,872	1,418,647	Oct 17 08:12 PM
Harris Todd	President and CEO	Oct 15 '24	Sale	24.31	10,035	243,970	1,467,338	Oct 17 08:12 PM
Harris Todd	Officer	Oct 16 '24	Proposed Sale	24.00	75,000	1,800,000		Oct 16 05:51 PM
Harris Todd	President and CEO	Sep 30 '24	Sale	24.00	500	12,000	1,477,373	Oct 02 05:38 PM
Harris Todd	President and CEO	Sep 23 '24	Sale	24.13	10,092	243,477	1,479,528	Sep 25 06:44 PM
Harris Todd	President and CEO	Sep 24 '24	Sale	24.02	1,055	25,341	1,478,473	Sep 25 06:44 PM
Harris Todd	President and CEO	Sep 25 '24	Sale	24.01	600	14,406	1,477,873	Sep 25 06:44 PM
Harris Todd	President and CEO	Sep 20 '24	Sale	24.19	7,109	171,950	1,489,620	Sep 20 06:24 PM
Harris Todd	President and CEO	Sep 19 '24	Sale	24.31	5,698	138,491	1,496,729	Sep 20 06:24 PM
Harris Todd	President and CEO	Sep 18 '24	Sale	24.00	3,500	84,000	1,502,427	Sep 20 06:24 PM
Harris Todd	Officer	Sep 20 '24	Proposed Sale	24.00	60,000	1,440,000		Sep 20 04:49 PM
Harris Todd	Officer	Sep 18 '24	Proposed Sale	24.00	15,000	360,000		Sep 18 04:42 PM
Harris Irrevocable Trust 4 U/A	Member of immediate family of	Sep 18 '24	Proposed Sale	24.00	10,000	240,000		Sep 18 04:05 PM
Harris Irrevocable Trust 3 U/A	Member of immediate family of	Sep 18 '24	Proposed Sale	24.00	10,000	240,000		Sep 18 03:59 PM
Harris Irrevocable Trust 2 U/A	Member of immediate family of	Sep 18 '24	Proposed Sale	24.00	10,000	240,000		Sep 18 03:56 PM
Harris Irrevocable Trust 1 U/A	Member of immediate family of	Sep 18 '24	Proposed Sale	24.00	10,000	240,000		Sep 18 03:27 PM
KAPLAN GILLA	Director	Jun 13 '24	Option Exercise	0.61	61,392	37,449	89,623	Jun 18 05:01 PM
Bensen Daniel	Chief Operating Officer	Jun 10 '24	Sale	20.00	3,502	70,045	427,981	Jun 10 07:10 PM
Bensen Daniel	Chief Operating Officer	Jun 07 '24	Sale	20.00	200	4,000	431,483	Jun 10 07:10 PM
Bensen Daniel	Chief Operating Officer	Mar 11 '24	Sale	20.00	200	4,000	431,683	Mar 13 05:46 PM
Bensen Daniel	Chief Operating Officer	Mar 06 '24	Sale	20.09	1,733	34,819	431,951	Mar 08 05:38 PM
Bensen Daniel	Chief Operating Officer	Mar 07 '24	Sale	20.00	68	1,360	431,883	Mar 08 05:38 PM
Bensen Daniel	Chief Operating Officer	Mar 04 '24	Sale	20.08	5,063	101,654	434,873	Mar 05 05:40 PM
Bensen Daniel	Chief Operating Officer	Mar 01 '24	Sale	20.04	2,900	58,112	439,936	Mar 05 05:40 PM
Bensen Daniel	Chief Operating Officer	Mar 05 '24	Sale	20.02	1,189	23,802	433,684	Mar 05 05:40 PM
Bensen Daniel	Chief Operating Officer	Feb 28 '24	Sale	20.13	5,849	117,729	444,886	Feb 29 06:58 PM
Bensen Daniel	Chief Operating Officer	Feb 29 '24	Sale	20.00	2,050	41,003	442,836	Feb 29 06:58 PM
Bensen Daniel	Chief Operating Officer	Feb 27 '24	Sale	20.00	745	14,900	450,735	Feb 29 06:58 PM
Bensen Daniel	Chief Operating Officer	Feb 12 '24	Sale	20.00	1,501	30,020	451,480	Feb 14 09:00 PM
Bensen Daniel	Chief Operating Officer	Feb 07 '24	Sale	18.09	9,587	173,466	452,981	Feb 09 07:26 PM
Bensen Daniel	Chief Operating Officer	Feb 02 '24	Option Exercise	0.61	25,393	15,490	553,374	Feb 06 08:23 PM
Bensen Daniel	Chief Operating Officer	Feb 02 '24	Sale	16.33	75,393	1,231,097	477,981	Feb 06 08:23 PM
Bensen Daniel	Chief Operating Officer	Feb 06 '24	Sale	18.09	15,413	278,827	462,568	Feb 06 08:23 PM
Harris Todd	President and CEO	Feb 02 '24	Sale	16.50	86,183	1,421,655	1,516,514	Feb 06 08:22 PM
Harris Todd	President and CEO	Feb 05 '24	Sale	16.97	13,817	234,430	1,502,697	Feb 06 08:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TYRA

Tyra Biosciences Inc

Upgrade your FINVIZ experience